Researchers reported progress on nanovaccine platforms engineered to stimulate anti‑tumor immunity against hepatocellular carcinoma (HCC). The study described nanoparticle formulations that deliver tumor antigens and adjuvants to antigen‑presenting cells, eliciting robust T‑cell responses in preclinical HCC models. Authors outlined design parameters for lymphatic targeting, antigen presentation and immune activation specific to HCC’s immunosuppressive milieu. Preclinical results showed tumor growth delay and enhanced survival compared with controls. The work provides a translational roadmap for companies pursuing liver‑cancer vaccines and invites partnerships to advance IND‑enabling studies bridging nanomaterials, immunology and oncology.